GSK plc Sponsored ADR (GSK)
GSK shares rise 5% as it navigates vaccines woes to upgrade sales target
GSK PLC (LSE:GSK, NYSE:GSK) shares climbed 5% in early trading on Wednesday after the drugs giant appeared to shrug off vaccine-related woes and mollified the City by raising its long-term sales target. It is now expecting revenue to exceed £40 billion by 2031, up from £38 billion previously.
GSK upgrades long-term sales target; but Arexvy's struggles are confirmed
GSK PLC (LSE:GSK, NYSE:GSK) has raised its long-term revenue forecast, now expecting sales to exceed £40 billion by 2031, up from its previous £38 billion target. The upgrade comes after what the company described as a "strong" financial performance in 2024, driven by the growth of its specialty medicines portfolio.
GSK beats Q4 earnings estimates, lifts 2031 sales target
GSK forecast sales in 2025 to grow 3%-5% and reported better-than-expected fourth-quarter earnings, as strength in its HIV and oncology portfolio offset weakness in its vaccines division.
Earnings Preview: GSK (GSK) Q4 Earnings Expected to Decline
Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EMA Accepts GSK's Filing for Depemokimab in Two Respiratory Diseases
If approved, GSK's depemokimab will be the first ultra-long-acting biologic that requires only one dose every six months.
The RFK Jr. Effect: Biotech Stocks Brace For 'Games' In Senate Hearings
Biotech stocks will need to brace for political "games" Wednesday as the Senate meets to potentially confirm RFK Jr. to lead HHS. The post The RFK Jr. Effect: Biotech Stocks Brace For 'Games' In Senate Hearings appeared first on Investor's Business Daily.
GSK to explore cancer vaccines with Oxford University in £50mln deal
GSK PLC has unveiled plans to pour £50 million into research with Oxford University over vaccines to prevent some types of cancer. A GSK-Oxford Cancer Immuno-Prevention Programme would investigate how pre-cancerous cells develop, the FTSE 100 pharmaceutical said.
Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last?
Biotech and pharma dealmaking is off to a good start in 2025. Meanwhile, digital health fundraising defined by “David and Goliath dynamic” in 2024, report says.
GSK's Jemperli Gets EU Nod for Expanded Use in Endometrial Cancer
The European Commission approves GSK's Jemperli plus chemotherapy to treat all adult patients with primary, advanced or recurrent endometrial cancer.
Spero Therapeutics: Undervalued Based On Just Tebipenem And GSK Deal
Spero Therapeutics' tebipenem, an oral carbapenem for cUTIs, has high approval potential, supported by a successful phase 3 trial and a GSK licensing deal. The need for oral carbapenems is critical due to rising resistance to current oral treatments for complicated urinary tract infections. Tebipenem's success in the confirmatory phase 3 trial is highly probable, given its prior phase 3 success and publication in NEJM.
Hallucinations in AI: How GSK is addressing a critical problem in drug development
Hallucinations are a persistent problem in healthcare. Here's how GSK is using test-time compute scaling to improve its gen AI systems.
GSK plc (GSK) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
GSK plc (NYSE:GSK ) 43rd Annual J.P. Morgan Healthcare Conference January 14, 2025 10:30 AM ET Company Participants Emma Walmsley - CEO Luke Miels - Chief Commercial Officer Tony Wood - Chief Scientific Officer David Redfern - President Corporate Development Conference Call Participants James Gordon - JPMorgan James Gordon Good morning.
